Indications
Luxturna is indicated for the treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.
Composition
- Active substance
- voretigene neparvovec
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Luxturna
- Active substance
- voretigene neparvovec
- ATC code
- S01XA27
- Group
- Sensory organs
- Therapeutic area
- Leber Congenital Amaurosis, Retinitis Pigmentosa
- Marketing authorisation holder
- Novartis Europharm Limited
- Status
- Authorised